Le Lézard
Classified in: Health, Science and technology, Business, Covid-19 virus
Subjects: EARNINGS, Conference, Trade Show

SQZ Biotechnologies Reports Third Quarter 2021 Financial Results and Recent Portfolio Updates


SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today reported third quarter 2021 financial results and recent portfolio updates.

"This was another period of strong execution where we have continued to meaningfully advance our cell therapy platforms and clinical programs. We were pleased with the recent DSMB recommendation to advance our highest APC dose into combination with checkpoint inhibitors for patients with HPV16 positive cancers," said Armon Sharei, Ph.D., Chief Executive Officer at SQZ Biotechnologies. "We were also excited to announce that celiac disease will be the first autoimmune disease target for our TAC platform, with an IND submission projected for next year. These activities highlight our deep commitment to driving patient impact across disease areas through the implementation of innovative cell therapies."

Third Quarter 2021 and Recent Business and Portfolio Updates

SQZtm Antigen Presenting Cell ("APC") Platform in Oncology

SQZtm Enhanced Antigen Presenting Cell ("eAPC") Platform in Oncology

SQZtm Activating Antigen Carriers ("AAC") Platform in Oncology

SQZtm Tolerizing Antigen Carriers ("TAC") Platform in Immune Tolerance

SQZtm Potential Pipeline Expansion Research

Third Quarter 2021 Financial Highlights

About SQZ Biotechnologies

SQZ Biotechnologies Company is a clinical-stage biotechnology company focused on unlocking the full potential of cell therapies for patients around the world and has active programs in Oncology, Autoimmune and Infectious Diseases, as well as additional exploratory initiatives to support future pipeline growth. The company's proprietary Cell Squeeze® technology offers the unique ability to deliver multiple biological materials into many cell types to engineer what we believe can be a broad range of potential therapeutics. With demonstrated production timelines under 24 hours and the opportunity to eliminate preconditioning and lengthy hospital stays, our approach could significantly broaden the therapeutic range and accessibility of cell therapies. The company's first therapeutic applications seek to generate target-specific immune responses, both in activation for the treatment of solid tumors and infectious diseases, and in immune tolerance for the treatment of autoimmune diseases. For more information, please visit www.sqzbiotech.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements relating to our financial condition and cash position, platform development, manufacturing capabilities, product candidates, preclinical and clinical activities, outcomes and progress, development plans and execution, clinical efficacy, regulatory submissions, therapeutic impact, upcoming events and presentations, and market opportunities. These forward-looking statements are based on management's current expectations. Actual results could differ from those projected in any forward-looking statements due to several risk factors. Such factors include, among others, risks and uncertainties related to our limited operating history; our significant losses incurred since inception and expectation to incur significant additional losses for the foreseeable future; the development of our initial product candidates, upon which our business is highly dependent; the impact of the COVID-19 pandemic on our operations and clinical activities; our need for additional funding and our cash runway; the lengthy, expensive, and uncertain process of clinical drug development, including uncertain outcomes of clinical trials and potential delays in regulatory approval; our ability to maintain our relationships with our third party vendors; and protection of our proprietary technology, intellectual property portfolio and the confidentiality of our trade secrets. These and other important factors discussed under the caption "Risk Factors" in our Annual Report on Form 10-K, as updated by our Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2021 and other filings with the U.S. Securities and Exchange Commission could cause actual results to differ materially from those indicated by the forward-looking statements. Any forward-looking statements represent management's estimates as of this date and SQZ undertakes no duty to update these forward-looking statements, whether as a result of new information, the occurrence of current events, or otherwise, unless required by law.

Certain information contained in this press release relates to or is based on studies, publications, surveys and other data obtained from third-party sources and our own internal estimates and research. While we believe these third-party sources to be reliable as of the date of this press release, we have not independently verified, and we make no representation as to the adequacy, fairness, accuracy or completeness of any information obtained from third-party sources.

SQZ BIOTECHNOLOGIES COMPANY

Condensed Consolidated Statements of Operations

(In thousands, except share and per share amounts)

(unaudited)

 

 

THREE MONTHS ENDED

SEPTEMBER 30,

 

 

NINE MONTHS ENDED

SEPTEMBER 30,

 

 

2021

 

 

2020

 

 

2021

 

 

2020

Collaboration revenue

 

$

4,755

 

 

$

6,121

 

 

$

14,748

 

 

$

18,511

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

 

20,520

 

 

 

13,910

 

 

 

52,942

 

 

 

37,815

General and administrative

 

 

6,691

 

 

 

4,612

 

 

 

18,744

 

 

 

14,139

Operating expenses

 

 

27,211

 

 

 

18,522

 

 

 

71,686

 

 

 

51,954

Loss from operations

 

 

(22,456

)

 

 

(12,401

)

 

 

(56,938

)

 

 

(33,443)

Other income, net

 

 

6

 

 

 

50

 

 

 

19

 

 

 

523

Net loss

 

 

(22,450

)

 

 

(12,351

)

 

 

(56,919

)

 

 

(32,920)

Net loss per share attributable to common stockholders, basic and diluted

 

$

(0.80

)

 

$

(7.03

)

 

$

(2.08

)

 

$

(18.87)

Weighted-average common shares outstanding, basic and diluted

 

 

28,050,130

 

 

 

1,758,039

 

 

 

27,421,839

 

 

 

1,744,948

 

SQZ BIOTECHNOLOGIES COMPANY

Condensed Consolidated Balance Sheets

(In thousands)

(unaudited)

 

 

SEPTEMBER 30,

2021

 

 

DECEMBER 31,

2020

Assets

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

164,254

 

 

$

170,357

Other current assets

 

 

1,913

 

 

 

6,474

Total current assets

 

 

166,167

 

 

 

176,831

Other assets

 

 

77,906

 

 

 

54,310

Total assets

 

$

244,073

 

 

$

231,141

Liabilities and Stockholders' Equity

 

 

 

 

 

 

 

Current liabilities

 

 

39,109

 

 

 

45,193

Long term liabilities

 

 

71,758

 

 

 

58,749

Total liabilities

 

 

110,867

 

 

 

103,942

Total stockholders' equity

 

 

133,206

 

 

 

127,199

Total liabilities and stockholders' equity

 

$

244,073

 

 

$

231,141

 


These press releases may also interest you

16 mai 2022
In 2007, after many years in the recruiting industry and entrepreneurship in his DNA, TurningPoint's CEO & Founder, Ken Schmitt, decided it was time to change the standard for recruiting. He envisioned a high-touch, personalized approach to...

16 mai 2022
Mind Medicine (MindMed) Inc. , (NEO: MMED) (the "Company"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, announced today that the registration statement on Form S-3, filed on May 4, 2022, was...

16 mai 2022
Mydecine Innovations Group Inc. (NEO: MYCO) ("Mydecine" or the "Company"), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, today reported financial results and provided a business update for the...

16 mai 2022
According to the latest market analysis report "DNA Sequencing Market by Solution and Geography - Forecast and Analysis 2022-2026", the market will witness a YOY growth of 19.53% in 2022. The market is predicted to witness a potential growth...

16 mai 2022
ASC Therapeutics, a privately held biopharmaceutical company pioneering the development of transformative in-vivo gene replacement, gene editing and allogeneic cell therapies, will provide a comprehensive review of IND-enabling studies of ASC618, a...

16 mai 2022
CANbridge Pharmaceuticals Inc. (HKEX:1228), a leading China-based global biopharmaceutical company committed to the research, development and commercialization of transformative rare disease and rare oncology therapies, announced the presentation of...



News published on 10 november 2021 at 16:50 and distributed by: